You are here

Oncology Imaging

 

Five years ago the American Society of Clinical Oncology (ASCO) advised clinicians not to order advanced imaging or tumor marker tests for survivors of early-stage breast cancer. Yet the exam orders keep coming.

Reviewing brain MRI of close to 4,000 children as part of an ongoing population-based study, European neuroradiologists and neuroscientists discovered at least one incidental finding in more than one-quarter of the cohort.

The National Academy of Medicine announced Monday, Oct. 17, that it elected 80 new members, including Deborah Watkins Bruner, RN, PhD, a professor of radiation oncology at Emory University in Atlanta. 

A single 90-minute examination designed to assess chemotherapy-induced injuries of the brain, heart and joints among childhood cancer survivors has been proven feasible by a new study.

Starting annual screening mammography for breast cancer at age 40 helps detect a significant number of cancers, according to a recent study published in the American Journal of Roentgenology.

 

Recent Headlines

Radiotracer PET beats morphological imaging in prostate cancer analysis

PET imaging using the radiotracer 68GA-PMSA shows good promise for aiding early detection of lymph-node metastases in patients with recurrent prostate cancer, as researchers in Germany and the U.K. have shown the modality more accurate than morphological imaging—and likely capable of guiding salvage lymphadenectomy.

Oncology society’s data-analytics subsidiary growing fast

A year and a half after the American Society of Clinical Oncology (ASCO) and software partner SAP announced their CancerLinQ initiative to achieve better cancer care through big data, some 58 practices representing 1,000 providers around the country have signed on and are sharing insights from around 750,000 patient records.

Diffusion imaging zeroes in on specific prostate-cancer sections

The advanced diffusion-weighted imaging technique RSI, short for restriction-spectrum MRI, is able to detect variations in tumor grade with voxel-level precision—and so could aid in customizing treatment of prostate cancer patients whose disease is spreading faster in some tumor regions than others.  

FDA approves new PET agent for finding neuroendocrine tumors

The FDA has approved a kit used to prepare and inject a PET imaging agent that can ferret out rare somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients.

Gains made against colon cancer, but it’s hitting more people under 50

Overall rates of colorectal cancer have been dropping for years. That’s the good news. The bad news is that the disease is on the rise among young people.

Lifestyle factors emerge as the key variable in cancer avoidance, survivability

A major new analysis has entered the lifestyle vs. luck fray via JAMA Oncology, its authors having concluded that changes in lifestyle can ward off most cancers and that primary prevention ought to remain a priority for cancer control.

Precision oncology trounces traditional tumor treatment in major meta-analysis

After conducting a meta-analysis of 346 phase I clinical trials involving more than 13,000 cancer patients, researchers have found that outcomes are significantly better when treatment targets the molecular characteristics of the individual tumor than when older, anatomic site-based approaches are used. 

Colon cancer recurrences frequently not found until symptoms cause discomfort

When colorectal cancer comes back after initial surgical intervention, chances are it won’t be detected until troubling symptoms prompt the patient to make an unscheduled interval visit. 

Online patient info about pancreatic cancer practically requires a degree to understand

A readability analysis of 50 websites discussing treatment modalities for pancreatic cancer—one of the deadliest cancers and thus one of the most anxiety-producing after diagnosis—has found that, overall, the information is likely too hard to understand for vast swaths of the population.

Chemoradiation unnecessary for locally advanced pancreas cancer

An international phase 3 trial of patients with locally advanced, chemo-contained pancreatic cancer has found no significant difference in overall survival with chemoradiotherapy—a controversial treatment for this application—compared with chemotherapy alone. 

Pages